Expression of survivin and its four splice variants in colorectal cancer and its clinical significances

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Ge, Quan Xing ^a   Li, Yu Yuan ^a   Nie, Yu Qiang ^a   Zuo, Wen Ge ^a   Du, Yan Lei ^a  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

CEA; Colorectal cancer; Gene; Splice variants; Survivin

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; PROTEIN VARIANT; SURVIVIN; SURVIVIN 2ALPHA; SURVIVIN 2B; SURVIVIN 3B; SURVIVIN EX3; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; ISOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; BIOSYNTHESIS; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84874816606     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0535-6     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol: official journal of the European Society for Medical Oncology/ESMO. 2003;14(7):1026-38.
3. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2005;23(15):3526-35. doi: 10.1200/JCO.2005.00.695.
4. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92(2):212-6. doi: 10.1038/sj.bjc.6602340.
5. Reed JC, Bischoff JR. BIRinging chromosomes through cell division-and survivin' the experience. Cell. 2000;102(5):545-8.
6. Miura K, Fujibuchi W, Unno M. Splice isoforms as therapeutic targets for colorectal cancer. Carcinogenesis. 2012;33(12):2311-9. doi: 10.1093/carcin/ bgs347.
7. Gonen M, Weiser MR. Whither TNM? Semin Oncol. 2010;37(1):27-30. doi: 10.1053/j.seminoncol.2009.12.009.
8. Mitchell PJ, Ravi S, Grifftiths B, Reid F, Speake D, Midgley C, Mapstone N. Multicentre review of lymph node harvest in colorectal cancer: are we understaging colorectal cancer patients? Int J Colorectal Dis. 2009;24(8):915-21. doi: 10.1007/s00384-009-0697-z.
9. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 2003;23(4):3327-31.
10. Span PN, Tjan-Heijnen VC, Heuvel JJ, de Kok JB, Foekens JA, Sweep FC. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem. 2006;52(9):1693-700. doi: 10.1373/clinchem.2006.071613.
11. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem. 2006;281(2):1286-95. doi: 10.1074/jbc.M508773200.
12. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2003;9(3):931-46.
13. Pavlidou A, Dalamaga M, Kroupis C, Konstantoudakis G, Belimezi M, Athanasas G, Dimas K. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J gastroenterol: WJG. 2011;17(12):1614-21. doi: 10.3748/wjg.v17.i12.1614.
14. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24(8):875-84. doi: 10.1007/s00384-009-0725-z.
15. Xi RC, Biao WS, Gang ZZ. Significant elevation of survivin and living expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie. 2011;34(8-9):428-32. doi: 10.1159/000331132.
16. Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst. 2005;17(1):42-50.
17. Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H, Jin JS. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers. 2009;26(1):9-18. doi: 10.3233/DMA-2009-0598.
18. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, Siegel EM, Yeatman TJ, Shibata D. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10(3):188-93. doi: 10.1016/j.clcc.2011.03. 014.
19. Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006;6(4):305-11. doi: 10.3816/CCC.2006.n.049.
20. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012;105(6):520-8. doi: 10.1002/jso.22134.
21. Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL, Ha SW. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 2011;26(8):1019-23. doi: 10.1007/s00384-011-1180-1.
22. Fraunholz I, Rodel C, Distel L, Rave-Frank M, Kohler D, Falk S, Rodel F. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. Radiat Oncol. 2012;7:88. doi: 10.1186/1748-717X-7-88.
23. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91(11):2026-32.
24. Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol: WJG. 2004;10(19):2886-9.
25. Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG, Ma T. Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol: WJG. 2003;9(5):974-7.
26. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep. 2005;13(5):891-7.
27. Yie SM, Lou B, Ye SR, Cao M, He X, Li P, Hu K, Rao L, Wu SM, Xiao HB, Gao E. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15(11):3073-82. doi: 10.1245/s10434-008- 0069-x.
28. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4(3):174-91.
29. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59(24):6097-102.
30. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun. 2004;314(3):902-7.
31. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4(1):11. doi: 10.1186/1476-4598-4-11.
32. Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res. 2004;28(5):487-94. doi: 10.1016/j.leukres.2003.10.013.
33. Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol: WJG. 2004;10(22):3245-50.
34. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol. 2000;35(6):550-3.
35. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer (J int cancer). 2002;100(1):30-6. doi: 10.1002/ijc.10450.
36. Yamada Y, Kuroiwa T, Nakagawa T, Kajimoto Y, Dohi T, Azuma H, Tsuji M, Kami K, Miyatake S. Transcriptional expression of survivin and its splice variants in brain tumors in humans. J Neurosurg. 2003;99(4):738-45. doi: 10.3171/jns.2003.99.4.0738.
37. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002;86(5):737-43. doi: 10.1038/sj.bjc.6600153.
38. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002;9(12):1334-42. doi: 10.1038/sj.cdd.4401091.
39. Huang Y, Chen X, Chen N, Nie L, Xu M, Zhou Q. Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma. J Clin Pathol. 2011;64(11):953-9. doi: 10.1136/jclinpath-2011-200066.
40. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2011;17(11):3716-26. doi: 10.1158/1078-0432.CCR-11-0233.
41. Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst). 2010;. doi: 10.3233/ACP-2010-0537.
42. De Maria S, Pannone G, Bufo P, Santoro A, Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM, Staibano S, De Rosa G, Farina E, Emanuelli M, Santarelli A, Mariggio MA, Lo Russo L, Lo Muzio L. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(1):107-16. doi: 10.1007/s00432-008-0433-z.
43. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W, Stauber RH. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle. 2007;6(12):1502-9.
44. Sawai K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res. 2010;18(11-12):541-7.